Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells? ; volume:136 ; number:3 ; day:27 ; month:10 ; year:2012 ; pages:693-703 ; date:12.2012
Breast cancer research and treatment ; 136, Heft 3 (27.10.2012), 693-703, 12.2012
- Urheber
-
Sadanandam, Anguraj
Lal, Aseem
Benz, Stephen C.
Eppenberger-Castori, Serenella
Scott, Gary
Gray, Joe W.
Spellman, Paul
Waldman, Fred
Benz, Christopher C.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-012-2290-3
- URN
-
urn:nbn:de:101:1-2019101005581025364667
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sadanandam, Anguraj
- Lal, Aseem
- Benz, Stephen C.
- Eppenberger-Castori, Serenella
- Scott, Gary
- Gray, Joe W.
- Spellman, Paul
- Waldman, Fred
- Benz, Christopher C.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Genome profiling of ERBB2-amplified breast cancers
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Transcriptome and genome evolution during HER2-amplified breast neoplasia
Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
Her2/EGFR-PDGFR pathway aberrations associated with tamoxifen response in metastatic breast cancer patients
Nanoparticle delivery of TFOs is a novel targeted therapy for HER2 amplified breast cancer
Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer
Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Genome profiling of ERBB2-amplified breast cancers
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Transcriptome and genome evolution during HER2-amplified breast neoplasia
Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
Her2/EGFR-PDGFR pathway aberrations associated with tamoxifen response in metastatic breast cancer patients
Nanoparticle delivery of TFOs is a novel targeted therapy for HER2 amplified breast cancer
Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer
Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Genome profiling of ERBB2-amplified breast cancers
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Transcriptome and genome evolution during HER2-amplified breast neoplasia
Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
Her2/EGFR-PDGFR pathway aberrations associated with tamoxifen response in metastatic breast cancer patients
Nanoparticle delivery of TFOs is a novel targeted therapy for HER2 amplified breast cancer
Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer
Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers